CLOs on the Move

Hollister

www.hollister.com

 
Hollister Incorporated is an independently-owned global company that develops, manufactures and markets healthcare products, servicing over 90 countries. From the earliest days of our company, there has been a strong sense of community—a connection to people. That connection is embedded in the very fabric of our company, and as we continue to develop new products and services, we are focused on meeting the healthcare needs of people throughout the global community.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Nada Ardeleanu
 Associate General Counsel Profile
Melissa Brunette
 Senior Corporate Counsel and Chief Data Protection Counsel Profile

Similar Companies

Danaher

Danaher is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.

Excel Imaging Inc

Excel Imaging Inc is a Iowa Park, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akimeka, LLC

Akimeka, LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Kihei, HI. To find more information about Akimeka, LLC, please visit www.akimeka.com.

Rahd Oncology Products

Rahd Oncology Products is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.